{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:01:07Z","timestamp":1787497267105,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The microRNA (miR) cluster miR-143\/145 represents a well-characterized tumor-suppressive regulatory system with a multifaceted role in prostate cancer. Both miRs are consistently downregulated during disease progression, and their loss is associated with enhanced proliferation, invasion, epithelial\u2013mesenchymal transition, and metastatic competence. Mechanistically, the cluster modulates Rat Sarcoma Viral Oncogene Homolog (RAS)-Mitogen Activated Protein Kinase (MAPK) signaling via Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) and Extracellular Signal-Regulated Kinase 5 (ERK5), Tumor Protein p53 (p53)-dependent growth control through MYC Proto-Oncogene, Basic Helix-Loop-Helix Transcription Factor (c-MYC) repression, apoptosis via B-Cell Lymphoma 2 Interacting Protein 3 (BNIP3), and cytoskeleton-associated motility factors including Fascin Actin-Bundling Protein 1 (FSCN1), Human Enhancer of Filamentation 1\/ Neural Precursor Cell Expressed, Developmentally Down-Regulated Protein 9 (HEF1\/NEDD9), Golgi Membrane Protein 1 (GOLM1), and Fibronectin Type III Domain Containing 3B (FNDC3B). Downregulation is mainly driven by p53 dysfunction, promoter methylation, and RAS-dependent transcriptional repression. A defining feature is pronounced cell-type specificity, with tumor-suppressive effects in epithelial cells and context-dependent pro-angiogenic functions in stromal compartments, with direct translational relevance. Clinically, miR-143\/145 contribute to multimarker diagnostic signatures, while reduced miR-145 correlates with adverse pathology and biochemical recurrence. Preclinical replacement strategies reduce tumor growth and enhance docetaxel sensitivity, yet context-dependent effects necessitate cell type-specific delivery. Overall, the cluster represents a central regulator with diagnostic, prognostic, and therapeutic potential requiring prospective validation.<\/jats:p>","DOI":"10.1186\/s13062-026-00776-6","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:16:14Z","timestamp":1775888174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The miR-143\/145 cluster in prostate cancer: molecular regulation, context-dependent functions, and medical implications"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4129-8854","authenticated-orcid":false,"given":"Matthias B.","family":"Stope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger H. H.","family":"Erb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"776_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281\u201397.","journal-title":"Cell"},{"key":"776_CR2","first-page":"845","volume":"16","author":"Y Akao","year":"2006","unstructured":"Akao Y, Nakagawa Y, Naoe T. MicroRNA-143 and \u2013\u2009145 are possible common onco-microRNAs in human cancers. Oncol Rep. 2006;16:845\u201350.","journal-title":"Oncol Rep"},{"key":"776_CR3","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1038\/onc.2012.495","volume":"32","author":"A Pagliuca","year":"2013","unstructured":"Pagliuca A, Valvo C, Fabrizi E, et al. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 2013;32:4806\u201313.","journal-title":"Oncogene"},{"key":"776_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/onc.2012.28","volume":"32","author":"J Zhang","year":"2013","unstructured":"Zhang J, Sun Q, Zhang Z, et al. Loss of microRNA-143\/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2\u2013p53 feedback loop. Oncogene. 2013;32:61\u20139.","journal-title":"Oncogene"},{"key":"776_CR5","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1158\/0008-5472.CAN-07-0533","volume":"67","author":"KP Porkka","year":"2007","unstructured":"Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67:6130\u20135.","journal-title":"Cancer Res"},{"key":"776_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/onc.2011.304","volume":"31","author":"ES Martens-Uzunova","year":"2012","unstructured":"Martens-Uzunova ES, Jalava SE, Dits NF, et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene. 2012;31:978\u201391.","journal-title":"Oncogene"},{"key":"776_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/ijc.26064","volume":"130","author":"S Wach","year":"2012","unstructured":"Wach S, Nolte E, Szczyrba J, et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer. 2012;130:611\u201321.","journal-title":"Int J Cancer"},{"key":"776_CR8","doi-asserted-by":"publisher","first-page":"1609646","DOI":"10.3389\/fphar.2025.1609646","volume":"16","author":"L Gan","year":"2025","unstructured":"Gan L, Li W, Chen Q, Cheng L, Zhang F, Zhong H, Lu Y, Zheng L, Qian B. MicroRNA-145 in urologic tumors: biological roles, regulatory networks, and clinical translation. Front Pharmacol. 2025;16:1609646.","journal-title":"Front Pharmacol"},{"key":"776_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1476-4598-9-136","volume":"9","author":"A Iio","year":"2010","unstructured":"Iio A, Nakagawa Y, Hirata I, Naoe T, Akao Y. Identification of non-coding RNAs embracing microRNA-143\/145 cluster. Mol Cancer. 2010;9:136.","journal-title":"Mol Cancer"},{"key":"776_CR10","doi-asserted-by":"crossref","unstructured":"Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. eLife. 2015;4:e05005.","DOI":"10.7554\/eLife.05005"},{"key":"776_CR11","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1997","volume":"6","author":"GA Calin","year":"2006","unstructured":"Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857\u201366.","journal-title":"Nat Rev Cancer"},{"key":"776_CR12","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nrg2634","volume":"10","author":"CM Croce","year":"2009","unstructured":"Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704\u201314.","journal-title":"Nat Rev Genet"},{"key":"776_CR13","doi-asserted-by":"publisher","first-page":"e0186658","DOI":"10.1371\/journal.pone.0186658","volume":"12","author":"C Johannessen","year":"2017","unstructured":"Johannessen C, Moi L, Kiselev Y, et al. Expression and function of the miR-143\/145 cluster in vitro and in vivo in human breast cancer. PLoS ONE. 2017;12:e0186658.","journal-title":"PLoS ONE"},{"key":"776_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1158\/1541-7786.MCR-09-0443","volume":"8","author":"J Szczyrba","year":"2010","unstructured":"Szczyrba J, L\u00f6prich E, Wach S, et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res. 2010;8:529\u201338.","journal-title":"Mol Cancer Res"},{"key":"776_CR15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/carcin\/bgr036","volume":"32","author":"SO Suh","year":"2011","unstructured":"Suh SO, Chen Y, Zaman MS, et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis. 2011;32:772\u20138.","journal-title":"Carcinogenesis"},{"key":"776_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature08199","volume":"460","author":"HI Suzuki","year":"2009","unstructured":"Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature. 2009;460:529\u201333.","journal-title":"Nature"},{"key":"776_CR17","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1073\/pnas.0808042106","volume":"106","author":"M Sachdeva","year":"2009","unstructured":"Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA. 2009;106:3207\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"776_CR18","doi-asserted-by":"publisher","first-page":"e114420","DOI":"10.1371\/journal.pone.0114420","volume":"9","author":"J Su","year":"2014","unstructured":"Su J, Li Z, Li X, et al. MiR-143 and miR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PLoS ONE. 2014;9:e114420.","journal-title":"PLoS ONE"},{"key":"776_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/1476-4598-13-220","volume":"13","author":"X Yan","year":"2014","unstructured":"Yan X, Chen X, et al. MicroRNA-143 and microRNA-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer. 2014;13:220.","journal-title":"Mol Cancer"},{"key":"776_CR20","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1101\/gad.1950610","volume":"24","author":"OA Kent","year":"2010","unstructured":"Kent OA, Chivukula RR, Mullendore M, et al. Repression of the miR-143\/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010;24:2754\u20139.","journal-title":"Genes Dev"},{"key":"776_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13073-016-0284-1","volume":"8","author":"MI Almeida","year":"2016","unstructured":"Almeida MI, Calin GA. The miR-143\/miR-145 cluster and the tumor microenvironment: unexpected roles. Genome Med. 2016;8:29.","journal-title":"Genome Med"},{"key":"776_CR22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/cancers12030708","volume":"12","author":"V Poli","year":"2020","unstructured":"Poli V, Secli L, Avalle L. The Microrna-143\/145 Cluster in Tumors: A Matter of Where and When. Cancers. 2020;12:708.","journal-title":"Cancers"},{"key":"776_CR23","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1038\/onc.2012.266","volume":"32","author":"OA Kent","year":"2013","unstructured":"Kent OA, Fox-Talbot K, Halushka MK. RREB1 repressed miR-143\/145 modulates KRAS signaling through downregulation of multiple targets. Oncogenes. 2013;32:2576\u201385.","journal-title":"Oncogenes"},{"key":"776_CR24","doi-asserted-by":"crossref","unstructured":"Clap\u00e9 C, Fritz V, Henriquet C, et al. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS ONE. 2009;4:e7542.","DOI":"10.1371\/journal.pone.0007542"},{"key":"776_CR25","first-page":"1606","volume":"114","author":"W Guo","year":"2013","unstructured":"Guo W, Ren D, Chen X, Tu X, Huang S, Wang M, Song L, Zou X, Peng X. HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145. J Cell Biol. 2013;114:1606\u201315.","journal-title":"J Cell Biol"},{"key":"776_CR26","first-page":"1093","volume":"38","author":"M Fuse","year":"2011","unstructured":"Fuse M, Nohate N, Kojima S, et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 2011;38:1093\u2013101.","journal-title":"Int J Oncol"},{"key":"776_CR27","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.1093\/nar\/gku461","volume":"42","author":"OA Kent","year":"2014","unstructured":"Kent OA, McCall MN, Cornish TC, Halushka MK. Lessons from miR-143\/145: the importance of cell-type localization of miRNAs. Nucleic Acids Res. 2014;42:7528\u201338.","journal-title":"Nucleic Acids Res"},{"key":"776_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-15-0854","volume":"6","author":"N Dimitrova","year":"2016","unstructured":"Dimitrova N, Gocheva V, Bhutkar A, et al. Stromal expression of miR-143\/145 promotes neoangiogenesis in lung cancer development. Cancer Discov. 2016;6:188\u2013201.","journal-title":"Cancer Discov"},{"key":"776_CR29","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/bjc.2011.520","volume":"106","author":"SB Villadsen","year":"2012","unstructured":"Villadsen SB, Bramsen JB, Ostenfeld MS, et al. The miR-143\/145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer. 2012;106:366\u201374.","journal-title":"Br J Cancer"},{"key":"776_CR30","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/cas.12280","volume":"104","author":"H Yoshino","year":"2013","unstructured":"Yoshino H, Enokida H, Itesako T, et al. Tumor-suppressive microRNA-143\/145 cluster targets hexokinase-2 in renal cell carcinoma. Cancer Sci. 2013;104:1567\u201374.","journal-title":"Cancer Sci"},{"key":"776_CR31","doi-asserted-by":"publisher","first-page":"6689","DOI":"10.1111\/j.1742-4658.2009.07383.x","volume":"276","author":"PM Borralho","year":"2009","unstructured":"Borralho PM, Kren BT, Castro RE, et al. MicroRNA-143 reduces viability and increases 5-fluorouracil sensitivity in HCT116 human colorectal cancer cells. FEBS J. 2009;276:6689\u2013700.","journal-title":"FEBS J"},{"key":"776_CR32","doi-asserted-by":"publisher","first-page":"70857","DOI":"10.18632\/oncotarget.12268","volume":"7","author":"Y Lin","year":"2016","unstructured":"Lin Y, Ge X, Wen Y, et al. MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. Oncotarget. 2016;7:70857\u201368.","journal-title":"Oncotarget"},{"key":"776_CR33","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/cdd.2009.117","volume":"17","author":"R Spizzo","year":"2010","unstructured":"Spizzo R, Nicoloso MS, Lupini L, et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-\u03b1 in human breast cancer cells. Cell Death Differ. 2010;17:246\u201354.","journal-title":"Cell Death Differ"},{"key":"776_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.addr.2014.10.031","volume":"81","author":"H Wang","year":"2015","unstructured":"Wang H, Jiang Y, Peng H, Chen Y, Zhu P, Huang Y. Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. Adv Drug Deliv Rev. 2015;81:142\u201360.","journal-title":"Adv Drug Deliv Rev"},{"key":"776_CR35","doi-asserted-by":"crossref","unstructured":"Kitade Y, Akao Y. MicroRNAs and their therapeutic potential for human diseases: microRNA-143 and colorectal cancer. J Pharmacol Sci. 2010;114:276\u201380.","DOI":"10.1254\/jphs.10R12FM"},{"key":"776_CR36","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.urolonc.2011.07.002","volume":"31","author":"KR Leite","year":"2013","unstructured":"Leite KR, Tomiyama A, Reis ST, et al. MicroRNA expression profiles in the progression of prostate cancer - from high-grade prostatic intraepithelial neoplasia to metastasis. Urol Oncol. 2013;31:796\u2013801.","journal-title":"Urol Oncol"},{"key":"776_CR37","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1158\/0008-5472.CAN-09-3718","volume":"70","author":"X Chen","year":"2010","unstructured":"Chen X, Gong J, Zeng H, et al. MicroRNA-145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res. 2010;70:2728\u201338.","journal-title":"Cancer Res"},{"key":"776_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/jhg.2013.121","volume":"59","author":"S Kojima","year":"2014","unstructured":"Kojima S, Enokida H, Yoshino H, et al. The tumor suppressive microRNA-143\/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet. 2014;59:78\u201387.","journal-title":"J Hum Genet"},{"key":"776_CR39","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.omtn.2019.02.020","volume":"16","author":"S Wach","year":"2019","unstructured":"Wach S, Brandl M, Borchardt H, et al. Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo. Mol Ther Nucleic Acids. 2019;16:272\u201383.","journal-title":"Mol Ther Nucleic Acids"},{"key":"776_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2407-13-61","volume":"13","author":"X Fan","year":"2013","unstructured":"Fan X, Chen X, Deng W, et al. Up-regulated microRNA-143 in cancer stem cells differentiation promotes prostate cancer cells metastasis by modulating FNDC3B expression. BMC Cancer. 2013;13:61.","journal-title":"BMC Cancer"},{"key":"776_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11010-010-0700-6","volume":"350","author":"B Xu","year":"2011","unstructured":"Xu B, Niu X, Zhang X, et al. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppressing KRAS. Mol Cell Biochem. 2011;350:207\u201313.","journal-title":"Mol Cell Biochem"},{"key":"776_CR42","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1073\/pnas.0510565103","volume":"103","author":"S Volinia","year":"2006","unstructured":"Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103:2257\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"key":"776_CR43","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1073\/pnas.0804549105","volume":"105","author":"PS Mitchell","year":"2008","unstructured":"Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer. Proc Natl Acad Sci USA. 2008;105:10513\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"776_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrclinonc.2011.76","volume":"8","author":"MA Cortez","year":"2011","unstructured":"Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids - the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8:467\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"776_CR45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrclinonc.2014.5","volume":"11","author":"H Schwarzenbach","year":"2014","unstructured":"Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11:145\u201356.","journal-title":"Nat Rev Clin Oncol"},{"key":"776_CR46","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1373\/clinchem.2015.241190","volume":"61","author":"Y He","year":"2015","unstructured":"He Y, Lin J, Kong D, et al. Current state of circulating microRNAs as cancer biomarkers. Clin Chem. 2015;61:1138\u201355.","journal-title":"Clin Chem"},{"key":"776_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/dna.2016.3426","volume":"36","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Song Y, Yao L, Song G, Teng C. Circulating microRNAs: promising biomarkers involved in several cancers and other diseases. DNA Cell Biol. 2017;36:77\u201394.","journal-title":"DNA Cell Biol"},{"key":"776_CR48","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jcmm.12236","volume":"18","author":"L Moldovan","year":"2014","unstructured":"Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med. 2014;18:371\u201390.","journal-title":"J Cell Mol Med"},{"key":"776_CR49","doi-asserted-by":"publisher","first-page":"50240","DOI":"10.18632\/oncotarget.16933","volume":"8","author":"D Vanacore","year":"2017","unstructured":"Vanacore D, Boccelino M, Rossetti S, et al. MicroRNAs in prostate cancer: an overview. Oncotarget. 2017;8:50240\u201351.","journal-title":"Oncotarget"},{"key":"776_CR50","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.addr.2014.05.009","volume":"81","author":"Y Chen","year":"2015","unstructured":"Chen Y, Gao DY, Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015;81:128\u201341.","journal-title":"Adv Drug Deliv Rev"},{"key":"776_CR51","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1038\/bjc.2013.250","volume":"108","author":"M Avgeris","year":"2013","unstructured":"Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br J Cancer. 2013;108:2573\u201381.","journal-title":"Br J Cancer"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00776-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00776-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00776-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:49:12Z","timestamp":1781646552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00776-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00776-6","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read the article, agreed to its content, and consent to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}